Lauren Hay
Analyst
Equibles does not estimate personal net worth.
About Lauren Hay
Lauren Hay has spoken on 5 earnings calls across 1 company, most recently for Ligand Pharmaceuticals Inc on August 6, 2026. The companies whose calls Lauren Hay spoke on are classified in the Healthcare sector.
Lauren Hay on recent calls
“Following the acquisition of Zoma Royalty, our commercial portfolio now consists of over 40 royalty revenue generating products with 15 key programs. The Zoma acquisition adds Roche's Vabizmo, Ojemda which is marketed by Cervier in the US and Ipsen in Europe, and Zevra's Miplifa.”
“We're in a very strong position as a business, with multiple drivers contributing to both near-term performance and long-term growth. Importantly, while Fulspari has become a major growth driver for LIGAN, it is only one component of a much broader growth story.”
“I'd like to provide more detail on our new portfolio management strategy that Todd touched on earlier. We recently launched a more sophisticated and systematic portfolio management process designed to actively drive value across our partnerships.”
“Turning to a portfolio review, I'd like to provide some important updates on LIGAN's key portfolio assets.”
“So, as you may be aware, Rekordati has recently started disclosing Carceba sales in their three year projection presentation a couple weeks ago. That showed impressive growth of 23% between 2023 in 2024.”